跳转至内容
Merck
CN

Y0000090

非那雄胺

European Pharmacopoeia (EP) Reference Standard

别名:

N-叔丁基-3-氧代-4-氮杂-5α-雄甾-1-烯-17β-甲酰胺, MK-906, N-(2-甲基-2-丙基)-3-氧代-4-氮杂-5α-雄甾-1-烯-17β-甲酰胺

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C23H36N2O2
化学文摘社编号:
分子量:
372.54
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

finasteride

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H][C@@]12CC[C@@]3([H])[C@]4([H])CC[C@H](C(=O)NC(C)(C)C)[C@@]4(C)CC[C@]3([H])[C@@]1(C)C=CC(=O)N2

InChI

1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

InChI key

DBEPLOCGEIEOCV-WSBQPABSSA-N

Gene Information

human ... SRD5A2(6716)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Finasteride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

选择性 5α-还原酶抑制剂;抗雄激素。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under 非那雄胺


pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

法规信息

涉药品监管产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



James Tacklind et al.
The Cochrane database of systematic reviews, (10)(10), CD006015-CD006015 (2010-10-12)
Benign prostatic hyperplasia (BPH), a non-malignant enlargement of the prostate in aging men, can cause bothersome urinary symptoms (intermittency, weak stream, straining, urgency, frequency, incomplete emptying). Finasteride, a five-alpha reductase inhibitor (5ARI), blocks the conversion of testosterone to dihydrotestosterone, reduces
Manlio A Goetzl et al.
Nature clinical practice. Urology, 3(8), 422-429 (2006-08-12)
Prostate cancer chemoprevention involves the use of natural and/or synthetic agents that inhibit or reverse the development of precancerous lesions or delay progression of these lesions to invasive disease. The recent completion of the first Phase III trial for prostate
José Manuel Mella et al.
Archives of dermatology, 146(10), 1141-1150 (2010-10-20)
Androgenetic alopecia is the most common form of alopecia in men. To determine the efficacy and safety of finasteride therapy for patients with androgenetic alopecia. MEDLINE, EMBASE, CINAHL, Cochrane Registers, and LILACS were searched for randomized controlled trials reported in



全球贸易项目编号

货号GTIN
Y000009004061837567780